TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Price, Forecast & Analysis
USA - NYSE:TEVA - US8816242098 - ADR
TEVA Key Statistics, Chart & Performance
The current stock price of TEVA is 25.735 USD. In the past month the price increased by 24.96%. In the past year, price increased by 52.95%.
TEVA Latest News, Press Relases and Analysis
TEVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.19 | 961.32B | ||
| JNJ | JOHNSON & JOHNSON | 18.72 | 468.02B | ||
| MRK | MERCK & CO. INC. | 10.36 | 228.01B | ||
| PFE | PFIZER INC | 8.05 | 146.43B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.49 | 100.01B | ||
| ZTS | ZOETIS INC | 19.15 | 53.79B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.72 | 23.29B | ||
| VTRS | VIATRIS INC | 4.72 | 12.83B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.08 | 11.01B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.41 | 8.29B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.09B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.9 | 3.99B |
Related stock screener links
About TEVA
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
TEVA PHARMACEUTICAL-SP ADR
124 Dvora Hanevi'a St.
TEL AVIV-YAFO 49131 IL
CEO: Kare Schultz
Employees: 33892
Phone: 97239148213
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What does TEVA do?
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
What is the current price of TEVA stock?
The current stock price of TEVA is 25.735 USD. The price increased by 2.41% in the last trading session.
What is the dividend status of TEVA PHARMACEUTICAL-SP ADR?
TEVA does not pay a dividend.
What is the ChartMill rating of TEVA PHARMACEUTICAL-SP ADR stock?
TEVA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists TEVA stock?
TEVA stock is listed on the New York Stock Exchange, Inc. exchange.
Can you provide the sector and industry classification for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for TEVA stock?
TEVA PHARMACEUTICAL-SP ADR (TEVA) currently has 33892 employees.
TEVA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TEVA. When comparing the yearly performance of all stocks, TEVA is one of the better performing stocks in the market, outperforming 91.63% of all stocks.
TEVA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TEVA. TEVA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
TEVA Financial Highlights
Over the last trailing twelve months TEVA reported a non-GAAP Earnings per Share(EPS) of 2.7. The EPS decreased by -3.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| Debt/Equity | 2.46 |
TEVA Forecast & Estimates
9 analysts have analysed TEVA and the average price target is 0.06 USD. This implies a price decrease of -99.78% is expected in the next year compared to the current price of 25.735.
For the next year, analysts expect an EPS growth of 5.48% and a revenue growth 2.79% for TEVA